TuHURA Biosciences (NASDAQ:HURA) Shares Break Below 200 Day Moving Average – Time to Sell?

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s stock price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.96 and traded as low as $1.85. TuHURA Biosciences shares last traded at $1.93, with a volume of 519,359 shares traded.

Wall Street Analysts Forecast Growth

HURA has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, October 27th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, TuHURA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Trading Down 6.3%

The stock has a market capitalization of $123.00 million, a PE ratio of -3.57 and a beta of -0.21. The company has a current ratio of 0.18, a quick ratio of 0.18 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average is $2.02 and its two-hundred day moving average is $1.96.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts predict that TuHURA Biosciences, Inc. will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On TuHURA Biosciences

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $1,615,000. Apollon Wealth Management LLC boosted its stake in shares of TuHURA Biosciences by 17.7% in the first quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock valued at $283,000 after purchasing an additional 23,717 shares during the period. Cetera Investment Advisers purchased a new position in shares of TuHURA Biosciences in the first quarter valued at $251,000. Bank of New York Mellon Corp acquired a new stake in TuHURA Biosciences during the 2nd quarter valued at $285,000. Finally, WealthShield Partners LLC acquired a new stake in TuHURA Biosciences during the 1st quarter valued at $164,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.